XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
US Stock MarketDetailed Quotes
VRCA Verrica Pharmaceuticals
- 0.737
- +0.085+13.02%
Close Feb 14 16:00 ET
- 0.740
- +0.003+0.43%
Post 20:01 ET
66.73MMarket Cap-0.40P/E (TTM)
0.757High0.653Low469.11KVolume0.660Open0.652Pre Close339.93KTurnover1.09%Turnover RatioLossP/E (Static)90.56MShares11.41052wk High-1.96P/B31.78MFloat Cap0.61152wk Low--Dividend TTM43.13MShs Float23.290Historical High--Div YieldTTM15.84%Amplitude0.611Historical Low0.724Avg Price1Lot Size
Trending Stocks
Discussing
Many institutions are bullish! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. 🎙️Discussion: 1
Popular on moomoo
Feb 13 17:34
China's asset revaluation sparks debate: What are mooers buying?
Verrica Pharmaceuticals Stock Forum
Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference
Tuesday, 21st January at 7:00 am
– Presented data includes a 97% Calculated Objective Response Rate (ORR) of study subjects following treatment with VP-315
– Posters highlight the safety data, tolerability data, and antitumor efficacy data of VP-3...
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
Friday, 6th December at 8:00 am
WEST CHESTER, Pa., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced its develop...
WEST CHESTER, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the acceptanc...
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure
- Sales and marketing efforts to focus on pediatricians and expand access beyond dermatologists
WEST CHESTER, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing med...
Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
Verrica Pharmaceuticals announced positive preliminary results from Part 2 of its Phase 2 clinical trial for VP-315, an investigational oncolytic peptide-based immunotherapy for basal cell carcinoma(BCC). Key findings include:
-...
No comment yet